- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.12.25 | Annexin Pharmaceuticals AB: First patients treated in Annexin's Phase 2a study in diabetic retinopathy and RVO | 95 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces that the first two patients have been dosed in the company's Proof of Concept Phase 2a study with the drug candidate ANXV in diabetic retinopathy (DR) and... ► Artikel lesen | |
| 16.09.25 | Annexin Pharmaceuticals AB: Annexin appoints world-leading ophthalmology experts to Medical Advisory Board | 135 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB has appointed a Medical Advisory Board in Ophthalmology. The independent clinical experts in the Board will act as key advisors to the Annexin team advancing the clinical... ► Artikel lesen | |
| 07.08.25 | Annexin Pharmaceuticals AB: Annexin receives approval for Phase 2a study in diabetic retinopathy and RVO | 201 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to start a clinical Proof of Concept phase 2a study with the drug candidate ANXV... ► Artikel lesen | |
| 28.05.25 | XFRA NEW INSTRUMENTS AVAILABLE ON 28.05.2025 | 1.397 | Xetra Newsboard | The following instruments on XETRA do have their first trading 28.05.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 28.05.2025
Aktien
1 CNE100006XS6 Jiangsu Hengrui Pharmaceuticals... ► Artikel lesen | |
| 27.05.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 27.05.2025 | 686 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 27.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 27.05.2025ISIN NameCA42841L1085 HI-VIEW... ► Artikel lesen | |
| ANNEXIN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 27.05.25 | XFRA ISIN CHANGE | 666 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA82888R1055 Simply Better Brands Corp. 27.05.2025 CA89778A1003 Trubar Inc. 28.05.2025 Tausch 1:1SE0009664154 Annexin... ► Artikel lesen | |
| 27.05.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 27.05.2025 | 717 | Xetra Newsboard | Das Instrument 6RJ US7731221062 ROCKET LAB USA A DL-,0001 EQUITY wird ex Kapitalmassnahme gehandelt am 27.05.2025 The instrument 6RJ US7731221062 ROCKET LAB USA A DL-,0001 EQUITY is traded ex capital... ► Artikel lesen | |
| 26.05.25 | Reverse Split and Change of ISIN for Annexin Pharmaceuticals AB | 533 | GlobeNewswire | Referring to the press release from Annexin Pharmaceuticals AB's on 21 May, the company will carry out a reverse stock split in relations 1:100. The share will be traded under new ISIN code with... ► Artikel lesen | |
| 03.03.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 03.03.2025 | 609 | Xetra Newsboard | Das Instrument MBG DE0007100000 MERCEDES-BENZ GRP NA O.N. EQUITY wird ex Kapitalmassnahme gehandelt am 03.03.2025 The instrument MBG DE0007100000 MERCEDES-BENZ GRP NA O.N. EQUITY is traded ex capital... ► Artikel lesen | |
| 06.02.25 | Annexin Pharmaceuticals AB: Annexin resolves on a rights issue of approximately SEK 50 million, secured to approximately 80 percent, subject to approval by the Extraordinary General Meeting | 416 | GlobeNewswire (Europe) | NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, RUSSIA, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR NEW... ► Artikel lesen |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MOONLAKE IMMUNOTHERAPEUTICS | 18,610 | +29,69 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| CG ONCOLOGY | 54,30 | +29,49 % | CG Oncology Inc.: CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial... ► Artikel lesen | |
| AKTIS ONCOLOGY | 22,460 | 0,00 % | Aktis Oncology: Erster US-Börsengang des Jahres - die Hintergründe | Die Wall Street kann sich in Kürze über ein weiteres Biotech-Unternehmen freuen. Der Radiopharma-Spezialist Aktis Oncology strebt an die Nasdaq und will mit dem Listing einen dreistelligen Millionen-Dollar-Betrag... ► Artikel lesen | |
| QIAGEN | 41,230 | -0,15 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 26,245 | +12,74 % | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,805 | -0,18 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 24,250 | -4,19 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering | BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. ("Monte Rosa") (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines... ► Artikel lesen | |
| ALUMIS | 19,550 | +7,59 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 34,580 | -2,87 % | Vifor International AG (CSL Vifor): CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy | FILSPARI® (sparsentan) suggested for IgA Nephropathy patients who are at risk of progressive kidney function loss
ST. GALLEN, Switzerland, and SAN DIEGO, Sept. 26, 2025 /PRNewswire/... ► Artikel lesen | |
| ERASCA | 6,705 | +14,81 % | What's Going With Cancer Biotech Erasca Stock On Thursday? | ||
| AVIDITY BIOSCIENCES | 72,39 | +0,06 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ARCELLX | 66,31 | +3,11 % | UBS initiates Arcellx stock coverage with Buy rating, $100 price target | ||
| ARS PHARMACEUTICALS | 13,130 | +19,91 % | ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating | ||
| COGENT BIOSCIENCES | 35,330 | -0,67 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis | WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| TANGO THERAPEUTICS | 11,820 | +6,92 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor | Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately... ► Artikel lesen |
ANNEXIN PHARMACEUTICALS AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,710 Euro und damit +2,40 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ANNEXIN PHARMACEUTICALS AB finden Sie auf Wallstreet Online.